Paper Details
- Home
- Paper Details
FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia.
Author: ByKunthel, Del VallePedro L, FarrellAnn T, GoldbergKirsten B, LeongRuby, LiuChao, NorsworthyKelly J, PazdurRichard, PrzepiorkaDonna, ShenYuan-Li, ShethChristopher M, SubramaniamSriram, ZhuangLuning
Original Abstract of the Article :
On November 21, 2018, the FDA approved glasdegib (Daurismo; Pfizer), a small-molecule Hedgehog inhibitor, in combination with low-dose cytarabine (LDAC) for treatment of newly diagnosed acute myeloid leukemia (AML) in adults ≥ 75 years or with comorbidities that preclude use of intensive induc...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1158/1078-0432.CCR-19-0365
データ提供:米国国立医学図書館(NLM)
A New Treatment Option for Acute Myeloid Leukemia (AML): FDA Approves Glasdegib
This article announces the FDA approval of glasdegib, a small-molecule Hedgehog inhibitor, in combination with low-dose cytarabine (LDAC), for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults. This approval is significant as it provides a new treatment option for AML patients who are not eligible for intensive induction chemotherapy, often due to age or comorbidities.
Glasdegib Offers Hope for AML Patients
Clinical trials have demonstrated that glasdegib combined with LDAC improves overall survival compared to LDAC alone. This is a valuable finding as it offers a potentially life-saving treatment option for a group of patients who previously had limited treatment choices. It's like discovering a new spring of water in the heart of a parched desert, bringing hope and relief to those who were desperate for hydration.
Understanding the Implications of Glasdegib's Approval
While this approval is a significant step forward, it is important to note that glasdegib is not without potential side effects. The FDA label includes boxed warnings for embryo-fetal toxicity and QT interval prolongation. It is crucial to discuss the potential benefits and risks of this treatment with a healthcare professional to make informed decisions about treatment options. It's like carefully navigating a treacherous desert landscape, understanding the potential hazards and taking precautions to ensure a safe journey.
Dr. Camel's Conclusion
The approval of glasdegib is a testament to the ongoing quest for innovative cancer treatments. This new option offers hope for AML patients who have limited treatment choices, providing a lifeline in the desert of cancer care. However, it's important to remember that this is just one step in the journey. Continued research is essential to understand the long-term impact of glasdegib and to develop even more effective treatments for AML.
Date :
- Date Completed 2020-09-21
- Date Revised 2020-09-21
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.